The Effects of Clinofibrate on Quantitative and Qualitative Abnormalities of Plasma Lipoproteins

DOI Web Site Open Access
  • HARA Yasushi
    Department of Internal Medicine, Tane General Hospital
  • SATO Akira
    Division of Atherosclelosis, Metabolism and Clinical Nutrition, National Cardiovascular Center
  • YOKOTA Chiaki
    Division of Atherosclelosis, Metabolism and Clinical Nutrition, National Cardiovascular Center
  • IKEDA Kayoko
    Division of Atherosclelosis, Metabolism and Clinical Nutrition, National Cardiovascular Center
  • TSUIMA Motoo
    Division of Atherosclelosis, Metabolism and Clinical Nutrition, National Cardiovascular Center
  • SUZUKI Masaaki
    Division of Atherosclelosis, Metabolism and Clinical Nutrition, National Cardiovascular Center
  • KAGEYAMA Aritsune
    関西医科大学第1内科
  • NAKAO Yasuhiko
    関西医科大学第1内科
  • KATAYAMA Yoshiaki
    国立循環器病センター検査部
  • HARANO Yutaka
    Division of Atherosclelosis, Metabolism and Clinical Nutrition, National Cardiovascular Center

Bibliographic Information

Other Title
  • 高トリグリセライド血症におけるClinofibrateのリポ蛋白の量および質的異常の改善効果

Search this article

Description

Seven patients with hypertriglyceridemia were studied. Those patients consisted of 2 type IIb and 5 type IV hyperlipidemia. The patients were given 600mg/day or 1200mg/day of clinofibrate every day for 4-12 weeks. The lipoproteins were fractionated by ultracentrifugation by Hatch and Lees' method before and after clinofibrate treatment.<br>In each lipoprotein fraction, TG, Chol and ApoB were measured. Plasma triglyceride decreased by 37.3% and VLDL-TG by 39%. Total cholesterol decreased by 12.6% and VLDL-Chol by 52%. IDL-Chol decrased by 32.5%. VLDL-Apo B decreased significantly. The results indicate that Clinofibrate treatment reduced Chol, TG and Apo B content in VLDL, and that treatment decreased the number of VLDL particles.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top